MX2021012994A - Administracion heterologa de vacunas tau. - Google Patents
Administracion heterologa de vacunas tau.Info
- Publication number
- MX2021012994A MX2021012994A MX2021012994A MX2021012994A MX2021012994A MX 2021012994 A MX2021012994 A MX 2021012994A MX 2021012994 A MX2021012994 A MX 2021012994A MX 2021012994 A MX2021012994 A MX 2021012994A MX 2021012994 A MX2021012994 A MX 2021012994A
- Authority
- MX
- Mexico
- Prior art keywords
- tau peptides
- tau
- composition containing
- peptides
- vaccines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen métodos para inducir una respuesta inmune contra la proteína tau en un sujeto que padece de una enfermedad, trastorno o condición neurodegenerativa, tal como la Enfermedad de Alzheimer; los métodos incluyen administrar una composición de imprimación liposomal que contienen péptidos tau, preferiblemente péptidos tau fosforilados, y una composición de refuerzo conjugada que contiene péptidos tau, preferiblemente péptidos tau fosforilados, conjugados a un portador inmunogénico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962837987P | 2019-04-24 | 2019-04-24 | |
PCT/US2020/029477 WO2020219646A1 (en) | 2019-04-24 | 2020-04-23 | Heterologous administration of tau vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012994A true MX2021012994A (es) | 2022-03-04 |
Family
ID=72921263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012994A MX2021012994A (es) | 2019-04-24 | 2020-04-23 | Administracion heterologa de vacunas tau. |
Country Status (17)
Country | Link |
---|---|
US (2) | US11591377B2 (es) |
EP (1) | EP3965817A4 (es) |
JP (1) | JP2022529529A (es) |
KR (1) | KR20220005033A (es) |
CN (1) | CN114173812A (es) |
AU (1) | AU2020262899A1 (es) |
BR (1) | BR112021021213A2 (es) |
CA (1) | CA3137884A1 (es) |
EA (1) | EA202192891A1 (es) |
IL (1) | IL287486A (es) |
JO (1) | JOP20210284A1 (es) |
MA (1) | MA55902A (es) |
MX (1) | MX2021012994A (es) |
SG (1) | SG11202111770RA (es) |
TW (1) | TW202110478A (es) |
WO (1) | WO2020219646A1 (es) |
ZA (1) | ZA202108168B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA50465A (fr) | 2017-10-25 | 2020-09-02 | Ac Immune Sa | Compositions de peptides tau phosphorylés et leurs utilisations |
KR20210125048A (ko) | 2019-02-08 | 2021-10-15 | 에이씨 이뮨 에스.에이. | 인산화 타우 펩티드 백신의 안전한 투여 방법 |
AU2022328342A1 (en) * | 2021-08-12 | 2024-02-22 | Ac Immune Sa | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses |
AU2022356435A1 (en) * | 2021-09-29 | 2024-03-28 | Ac Immune Sa | Method of safe administration of tau phosphopeptide conjugate |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
DE69318420T2 (de) | 1992-12-14 | 1999-01-28 | Innogenetics Nv | Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
AU2001273361A1 (en) | 2000-07-11 | 2002-01-21 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
AU2003203079B9 (en) | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
KR100994748B1 (ko) | 2002-04-19 | 2010-11-17 | 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 | 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물 |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
CA2633399C (en) | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
CN101965365A (zh) | 2007-10-19 | 2011-02-02 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
ES2885398T3 (es) | 2009-03-18 | 2021-12-13 | Ac Immune Sa | Método para uso terapéutico |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
EP3329932A1 (en) | 2009-06-10 | 2018-06-06 | New York University | Immunological targeting of pathological tau proteins |
IN2012DN00446A (es) | 2009-07-30 | 2015-05-15 | Pfizer Vaccines Llc | |
US9289488B2 (en) | 2010-08-12 | 2016-03-22 | Ac Immune Sa | Vaccine engineering |
CN103189050B (zh) | 2010-10-26 | 2017-09-29 | Ac免疫有限公司 | 包含通过疏水部分修饰的肽的基于脂质体的构建体 |
WO2015122922A1 (en) * | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
KR20170023124A (ko) | 2014-06-26 | 2017-03-02 | 얀센 백신스 앤드 프리벤션 비.브이. | 미세소관-연관 단백질 타우에 특이적으로 결합하는 항체 및 항원-결합 단편 |
SG10201911349YA (en) | 2015-06-05 | 2020-01-30 | Genentech Inc | Anti-tau antibodies and methods of use |
EP3551220A1 (en) * | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of use |
MA50465A (fr) * | 2017-10-25 | 2020-09-02 | Ac Immune Sa | Compositions de peptides tau phosphorylés et leurs utilisations |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
-
2020
- 2020-04-23 KR KR1020217038109A patent/KR20220005033A/ko unknown
- 2020-04-23 AU AU2020262899A patent/AU2020262899A1/en active Pending
- 2020-04-23 CA CA3137884A patent/CA3137884A1/en active Pending
- 2020-04-23 MA MA055902A patent/MA55902A/fr unknown
- 2020-04-23 MX MX2021012994A patent/MX2021012994A/es unknown
- 2020-04-23 WO PCT/US2020/029477 patent/WO2020219646A1/en unknown
- 2020-04-23 TW TW109113654A patent/TW202110478A/zh unknown
- 2020-04-23 SG SG11202111770RA patent/SG11202111770RA/en unknown
- 2020-04-23 JO JOP/2021/0284A patent/JOP20210284A1/ar unknown
- 2020-04-23 JP JP2021563196A patent/JP2022529529A/ja active Pending
- 2020-04-23 US US16/856,400 patent/US11591377B2/en active Active
- 2020-04-23 CN CN202080046201.9A patent/CN114173812A/zh active Pending
- 2020-04-23 EP EP20796144.2A patent/EP3965817A4/en active Pending
- 2020-04-23 BR BR112021021213A patent/BR112021021213A2/pt unknown
- 2020-04-23 EA EA202192891A patent/EA202192891A1/ru unknown
-
2021
- 2021-10-21 IL IL287486A patent/IL287486A/en unknown
- 2021-10-22 ZA ZA2021/08168A patent/ZA202108168B/en unknown
-
2023
- 2023-02-20 US US18/171,498 patent/US20230257433A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230257433A1 (en) | 2023-08-17 |
BR112021021213A2 (pt) | 2021-12-21 |
EP3965817A4 (en) | 2023-11-22 |
WO2020219646A1 (en) | 2020-10-29 |
AU2020262899A1 (en) | 2021-11-18 |
EP3965817A1 (en) | 2022-03-16 |
MA55902A (fr) | 2022-03-16 |
JOP20210284A1 (ar) | 2023-01-30 |
EA202192891A1 (ru) | 2022-02-04 |
US20200339643A1 (en) | 2020-10-29 |
IL287486A (en) | 2021-12-01 |
JP2022529529A (ja) | 2022-06-22 |
CN114173812A (zh) | 2022-03-11 |
SG11202111770RA (en) | 2021-11-29 |
ZA202108168B (en) | 2022-09-28 |
KR20220005033A (ko) | 2022-01-12 |
CA3137884A1 (en) | 2020-10-29 |
US11591377B2 (en) | 2023-02-28 |
TW202110478A (zh) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012994A (es) | Administracion heterologa de vacunas tau. | |
PH12020550432A1 (en) | Compositions of phosphorylated tau peptides and uses thereof | |
Kawai et al. | DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy | |
KR20120098919A (ko) | 암의 치료제 | |
IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
ES2819282T3 (es) | Combinaciones de inhibidores de puntos de control inmunitarios | |
MX2021003421A (es) | Formulaciones de nanoparticulas lipidicas que comprenden compuestos peptidicos cationicos lipidados para el suministro de acidos nucleicos. | |
JP2015533376A5 (es) | ||
EA202192203A1 (ru) | СПОСОБ БЕЗОПАСНОГО ВВЕДЕНИЯ ВАКЦИНЫ ФОСФОРИЛИРОВАННОГО ПЕПТИДА Tau | |
CA2376894C (en) | Pharmaceutical composition comprising a protein and an ectoine | |
ES2951684T3 (es) | Métodos y composiciones para estimular la respuesta inmune | |
MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
JP6698541B2 (ja) | 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬 | |
JP2020528449A5 (es) | ||
RU2019113989A (ru) | Лекарственное средство | |
Yoshikawa et al. | Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma | |
JP2009530359A (ja) | 腫瘍成長の阻害 | |
ES2928331T3 (es) | Composiciones de variantes de anexina II y métodos | |
Zhao et al. | Cyclic Dinucleotide Self-Assembled Nanoparticles as a Carrier-Free Delivery Platform for STING-Mediated Cancer Immunotherapy | |
WO2000052045A3 (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
MX2022002293A (es) | Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso. | |
White et al. | Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid‐core‐peptides | |
CN109069599A (zh) | 针对癌症的基于ptp的疫苗 | |
WO1994022462A1 (fr) | Complexe immunomodulateur anti-sida | |
US20240041999A1 (en) | Therapeutic RNA for Treating Cancer |